MARKET

ITRM

ITRM

Iterum Therapeutics plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5384
-0.0197
-3.53%
After Hours: 0.5400 +0.0016 +0.30% 17:54 09/24 EDT
OPEN
0.5600
PREV CLOSE
0.5581
HIGH
0.5677
LOW
0.5312
VOLUME
3.83M
TURNOVER
--
52 WEEK HIGH
2.995
52 WEEK LOW
0.4510
MARKET CAP
98.41M
P/E (TTM)
-0.3316
1D
5D
1M
3M
1Y
5Y
BRIEF-Iterum Therapeutics PLC Says On Sept 7, Received A Letter From Nasdaq That Co Was Not In Compliance With Nasdaq Listing Rule
reuters.com · 09/10 21:27
Iterum Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings...
GlobeNewswire · 09/08 12:55
Iterum Therapeutics Sponsored Study Titled 'Azithromycin Plus Hydroxychloroquine for COVID-19 Infection' Withdrawn From ClinicalTrials.Gov Website; Says Inadequate Support To Carry Out Study
https://clinicaltrials.gov/ct2/show/NCT05026801
Benzinga · 08/30 16:36
Frazier Management Llc Buys Iovance Biotherapeutics Inc, Chinook Therapeutics Inc, Autolus ...
GuruFocus News · 08/13 18:38
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
BRIEF-Iterum Therapeutics Reports Second Quarter 2021 Financial Results
reuters.com · 08/13 11:27
Iterum Therapeutics Q2 Adj. EPS $(0.04) Beats $(0.06) Estimate
Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 95 percent increase over losses of $(0.80) per share from
Benzinga · 08/13 11:02
Iterum Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
--Type A meeting with FDA expected late Q3 to define pathway to potential approval for Oral Sulopenem following July's Complete Response Letter--
GlobeNewswire · 08/13 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ITRM. Analyze the recent business situations of Iterum Therapeutics plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ITRM stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 60
Institutional Holdings: 14.25M
% Owned: 7.80%
Shares Outstanding: 182.78M
TypeInstitutionsShares
Increased
6
2.75M
New
14
3.91M
Decreased
9
510.72K
Sold Out
19
2.58M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Brenton Ahrens
Chief Executive Officer/Director
Corey Fishman
Chief Financial Officer
Judith Matthews
Director
Michael Dunne
Independent Director
Mark Chin
Independent Director
Beth Hecht
Independent Director
Ronald Hunt
Independent Director
David Kelly
No Data
About ITRM
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. It is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. It has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms including methicillin-susceptible staphylococci, Streptococcus pyogenes and Streptococcus pneumonia.

Webull offers kinds of Iterum Therapeutics PLC stock information, including NASDAQ:ITRM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITRM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ITRM stock methods without spending real money on the virtual paper trading platform.